On September 1, 2020 DCprime, the front-runner in the field of relapse vaccines, and PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company with a unique intracellular delivery technology via PhotoChemical Internalisation, reported an extensive research collaboration (Press release, DCPrime, SEP 1, 2020, View Source [SID1234564214]). Within the collaboration, DCprime and PCI Biotech will combine their know-how and technology platforms to pursue the development of novel cancer vaccination concepts based on tumor-independent antigens (TIAs). The collaboration builds on preclinical proof-of-concept results previously presented by DCprime at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) in November 2019 and on PCI Biotech fimaVacc and fimaNAc technologies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The partnership is governed by a research collaboration agreement, under which the collaborators will perform an extensive evaluation of technology compatibility and synergy based on preclinical studies. The companies will evaluate results achieved from this research collaboration and then explore the potential for further development and partnership.
"We continue to innovate the cancer vaccine space and look forward to working closely with PCI Biotech on a ground-breaking off-the shelf vaccination concept for solid tumors addressing the huge need for novel antigen targets in oncology," said Erik Manting, CEO of DCprime. " Having access to PCI Biotech’s intracellular antigen delivery platforms and expertise will accelerate the development of therapeutic approaches based on the unique and novel principle we developed using tumor-independent antigens. This complements DCprime’s existing pipeline of relapse vaccines progressing through clinical trials in haematological malignancies."
"We are very pleased to collaborate with DCprime. This collaboration could reinforce the fimaVacc positive results obtained during a phase I study presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Immuno-Oncology Congress 2019, and the preclinical promising results obtained with fimaNAc, the PCI-mediated intracellular delivery of various types of "naked" mRNA molecules. Combining the complementary technologies of DCprime and PCI Biotech could lead to entirely new therapeutic clinical applications," commented Per Walday, CEO of PCI Biotech.